Nurix Therapeutics Swings to $549.8M Q3 Profit on Roche Collaboration Payment
Nurix Therapeutics, Inc. (NRIX) reported revenue of $673.1 million and net income of $549.8 million, or $4.73 per diluted share, for the third quarter ended August 31, 2026. The financial surge was primarily driven by a $653.2 million upfront license payment from its global collaboration with Roche. In the same quarter a year earlier, the company generated $7.9 million in revenue and posted a net loss of $86.4 million.
The massive influx of capital strengthened the company's balance sheet, bringing its total cash, cash equivalents, and marketable securities to $1.1 billion as of August 31, 2026, up from $592.9 million late last year. Management expects this cash position to extend its operational runway into the second half of 2029. Alongside financial growth, the company gained regulatory clearance for its Roche partnership and initiated its Phase 3 DAYBreak CLL-306 trial for bexobrutideg, dosing its first patient.
Looking ahead, investors will be monitoring progress across the company's clinical pipeline, including combination trials for bexobrutideg and Phase 1b expansion cohorts for oral CBL-B inhibitor NX-1607. Additionally, the company earned milestones from partners including Sanofi, Pfizer, and Gilead, while making a strategic decision to halt further clinical development of NX-2127.
Key points
- Nurix Therapeutics posted Q3 2026 net income of $549.8 million, up from a net loss of $86.4 million in Q3 2025.
- Quarterly revenue reached $673.1 million, largely due to a $653.2 million license payment from Roche.
- Cash and marketable securities totaled $1.1 billion as of August 31, 2026, extending funding into late 2029.
- The company initiated its Phase 3 DAYBreak CLL-306 trial for bexobrutideg after receiving regulatory clearance.
- Nurix decided to discontinue clinical development for NX-2127 while allowing active trial participants to continue treatment.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What were Nurix Therapeutics Q3 2026 financial results?
Nurix Therapeutics reported Q3 2026 revenue of $673.1 million and net income of $549.8 million, compared with revenue of $7.9 million and a net loss of $86.4 million in Q3 2025.
Why did Nurix Therapeutics revenue increase in Q3 2026?
Revenue increased primarily due to a $653.2 million license payment recognized from its global collaboration with Roche.
How long will Nurix Therapeutics cash reserves last?
With $1.1 billion in cash, cash equivalents, and marketable securities as of August 31, 2026, the company expects its cash runway to extend into the second half of 2029.